DVT

DVT announces Databricks partnership

Retrieved on: 
Wednesday, May 10, 2023
Comcast, Partnership, Professional, DVT, BI, Microsoft, Aptitude, Machine learning, Data Link Solutions, Artificial intelligence, Growth, Data science, Databricks, Airline

LONDON, May 10, 2023 /PRNewswire/ -- Global software and solutions company DVT has announced a new systems integration partnership with data and AI specialist and pioneer of the data lakehouse paradigm, Databricks .

Key Points: 
  • LONDON, May 10, 2023 /PRNewswire/ -- Global software and solutions company DVT has announced a new systems integration partnership with data and AI specialist and pioneer of the data lakehouse paradigm, Databricks .
  • The partnership will see DVT rapidly growing a team of certified Databricks engineers, integrators and skilled specialists to serve the demand for integrated Databricks solutions in South Africa, Africa, and further afield.
  • "The Databricks relationship was born of our longstanding, extensive and highly successful relationship with Microsoft, and was initiated by Databricks through DVT's European office in Ireland," says Damian Potter, Executive Head: Development, Data and Solutions, DVT.
  • "This partnership has been embraced by the Databricks EMEA leadership, and we aim to not only build up a solid competency for Africa, but also support our Middle East expansion plans by leveraging the Databricks partnership to aid our growth in this region."

Endologix Wins “Medical Device Engineering Breakthrough” Award in 7th Annual MedTech Breakthrough Awards Program

Retrieved on: 
Thursday, May 4, 2023
Health Technology, Health, Medical Devices, MAE, Femoral vein, Telehealth, Medical device, Amputation, Engineering, Pulmonary embolism, PBRC, Electronic health record, DVT, PTAB, Global health, Multimedia, Stent, Moyamoya disease, MD, Patient, Medical data breach, Risk, EHR, Vascular disease, IDE, FDA, Death, Treatment, Medtech, Pharmaceutical industry, Medical imaging, SFA

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that its DETOUR™ System has been selected as the winner of the “Medical Device Engineering Breakthrough” award in the 7th annual MedTech Breakthrough Awards.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that its DETOUR™ System has been selected as the winner of the “Medical Device Engineering Breakthrough” award in the 7th annual MedTech Breakthrough Awards.
  • This program is conducted by MedTech Breakthrough , an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.
  • “This award from MedTech Breakthrough is another strong validation of our strategy to expand our product portfolio into the large peripheral vascular market opportunity.
  • Congratulations to the Endologix team on being for our 2023 ‘Medical Device Engineering Breakthrough’ award.”
    *Lyden.

Global Deep Venous Disease Treatment Devices Market is Expected to Reach $2.4 Billion by 2032: Rise in Diagnosis of Deep Venous Diseases in Hospitals Leading to Increased Use of Treatment Devices - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 19, 2023
Health, Biotechnology, Innova, IVC, Lightning, Face, Boston Scientific, Food, COVID-19, DVT, Testosterone and the cardiovascular system, Vein, IPC, U.S. FDA, Incidence, Thrombectomy, Hospital, Acquisition, Lightning Flash, Patient, Risk, Serie A1 (water polo), National Medical Products Administration, Deep vein thrombosis, Growth, Diagnosis, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NMPA, Moyamoya disease, Medical device, Pharmaceutical industry, Health care, Birth control

The global deep venous disease treatment devices market is in the developed phase.

Key Points: 
  • The global deep venous disease treatment devices market is in the developed phase.
  • Among the sectors of the healthcare ecosystem that got less impacted by the pandemic are the deep venous disease treatment devices.
  • The global deep venous disease treatment devices market (by end user) is expected to be dominated by the hospitals and clinics segment.
  • The global deep venous disease treatment devices market (by region) is dominated by the North America segment.

Inovia Vein Marks Milestones in Raising Vein Disease and Therapy Awareness for 2023 DVT Awareness Month

Retrieved on: 
Monday, April 17, 2023
Managed Care, General Health, Health, Surgery, Volunteering, Pacific Northwest, Education, Volunteers in Medicine, Pulmonary embolism, Varicose veins, VIM, DVT, Deep vein thrombosis, MD, Patient, Risk, Lettuce big-vein disease, Pharmaceutical industry, Birth control, Nursing, Medical imaging, Central Oregon, Bend, Medicine

Inovia Vein Specialty Centers, a leading provider of vein disease treatments and therapies in the Pacific Northwest, announces its successful outreach and awareness efforts during DVT Awareness Month in March 2023.

Key Points: 
  • Inovia Vein Specialty Centers, a leading provider of vein disease treatments and therapies in the Pacific Northwest, announces its successful outreach and awareness efforts during DVT Awareness Month in March 2023.
  • Throughout the month of March, the clinic dedicated its resources to raising awareness about the dangers of vein disease, as well as providing support and educational resources to raise awareness about the dangers of DVT in our communities.
  • ABOUT INOVIA: Inovia Vein Specialty Centers is the largest vein care provider in the Northwest, with locations in NW Portland, Tigard, Happy Valley, Tanasbourne, and Bend.
  • Inovia Vein is home to Oregon’s leading vein surgeons offering minimally-invasive treatments for varicose veins, deep vein thrombosis (DVT), venous stasis ulcers and spider veins.

Allegro DVT Announces the Industry’s First MPEG-5 LCEVC Decoder Silicon IP

Retrieved on: 
Tuesday, April 4, 2023
Data Management, Consumer Electronics, Technology, Other Technology, Audio, Video, Software, Internet, LCEVC, SOC, HW, Silicon, V-NOVA, IPS, IP, MPEG, ISO, Television, DVT

Allegro DVT, a leading provider of silicon video IP solutions announces the availability of its D301, the first MPEG-5 Low Complexity Enhancement Video Coding (LCEVC) decoder IP solution.

Key Points: 
  • Allegro DVT, a leading provider of silicon video IP solutions announces the availability of its D301, the first MPEG-5 Low Complexity Enhancement Video Coding (LCEVC) decoder IP solution.
  • MPEG-5 part 2 LCEVC (Low Complexity Enhancement Video Coding) is the latest standard by MPEG and ISO.
  • The D301 LCEVC decoder IP is optimized for power and silicon area, making it suitable for system-on-chip (SoC) designers to easily integrate LCEVC decoding into their products.
  • Guido Meardi, CEO of V-Nova said: “We are very excited about Allegro DVT’s introduction of their LCEVC decoder IP.

Inovia Vein Leads Community Outreach for DVT Awareness Month

Retrieved on: 
Friday, March 24, 2023
General Health, Surgery, Other Health, Health, Managed Care, Pulmonary embolism, Varicose veins, DVT, Leg, Pain, Deep vein thrombosis, Patient, Swelling, Risk, Thrombosis, Death, Birth control, Medical imaging, Surgeon

In recognition of DVT Awareness Month , the Inovia Vein Specialty Centers have launched a community outreach campaign to raise awareness about Deep Vein Thrombosis (DVT) and encourage the public to become more aware of risks and to take preventative measures against this potentially life-threatening condition.

Key Points: 
  • In recognition of DVT Awareness Month , the Inovia Vein Specialty Centers have launched a community outreach campaign to raise awareness about Deep Vein Thrombosis (DVT) and encourage the public to become more aware of risks and to take preventative measures against this potentially life-threatening condition.
    "
  • If left untreated, DVT can lead to serious complications such as pulmonary embolism and even death," said Dr. Lauren Wikholm, Surgeon, at the Inovia Vein Specialty Centers in Happy Valley, Oregon.
  • ABOUT INOVIA: Inovia Vein Specialty Centers is the largest vein care provider in the Northwest, with locations in NW Portland, Tigard, Happy Valley, Tanasbourne, and Bend.
  • Inovia Vein is home to Oregon’s leading vein surgeons offering minimally-invasive treatments for varicose veins, deep vein thrombosis (DVT), venous stasis ulcers and spider veins.

Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through Regulatory, Clinical and Commercialization Phases

Retrieved on: 
Thursday, March 23, 2023
Well, Galway Clinic, SAB, IVC, KOL, Galway, Cardiovascular and Interventional Radiological Society of Europe, Society, Center of excellence, Intervention, Vision-guided robot systems, Consultant, Society of Interventional Radiology, Radiology, DVT, CIRSE, Prostate, Vein, SIR, Professor, Interventional radiology, Publication, Executive Committee, Clinical, SPC, European Board of Ophthalmology, Medical imaging

HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to receive global interest from interventional radiologists due to the gap in new innovative technology currently available on the market today. Microbot Medical, the company developing the LIBERTY® Robotic System, the first single-use endovascular robotic system, today announced that Professor Gerry O’Sullivan, a key opinion leader (KOL) from Ireland, has joined the Company’s Scientific Advisory Board (SAB). The Company believes the combination of his academic and medical experience will be invaluable while it seeks to establish Centers of Excellence throughout the U.S. and Europe in preparation for human clinical trials.

Key Points: 
  • Microbot Medical, the company developing the LIBERTY® Robotic System, the first single-use endovascular robotic system, today announced that Professor Gerry O’Sullivan, a key opinion leader (KOL) from Ireland, has joined the Company’s Scientific Advisory Board (SAB).
  • Annually, Professor O’Sullivan performs large volumes of prostate and uterine fibroid embolizations, as well as the full array of Interventional procedures.
  • “I believe interventional radiologists have been seeking a better solution to address their concerns, while still achieving favorable patient outcomes.
  • For a complete list and background on the members of the SAB, please visit the Company’s website at www.microbotmedical.com .

ether.fi Completes USD 5.3 Million Funding Round Co-led by NIV and Chapter One, Launches Liquid Staking Platform

Retrieved on: 
Wednesday, March 1, 2023
DSRV, Decentralized finance, USS Thomaston (LSD-28), Ecosystem, Chapter One, Maelstrom, ETH, NIV, Risk, Web3, NFT, Capital, DVT, Distribution, LSD, Version One Ventures, Treasury, Virtus Investment Partners, Kiln, Cryptocurrency, Ethereum

LONDON, March 1, 2023 /PRNewswire/ -- ether.fi, a liquid staking protocol designed with decentralization at its core, announced today that it has completed a USD$5.3m funding round co-led by investors North Island Ventures (NIV,) Chapter One, and Node Capital, with participation from Arrington Capital, Maelstrom, Version One Ventures and Purpose Investments.

Key Points: 
  • Node Capital, Arrington Capital, Maelstrom, Version One Ventures, and Purpose Investments also back staking protocol to address issues of centralized staking markets.
  • As a decentralized non-custodial staking solution, ether.fi allows stakers to retain control of their keys while delegating validator operations to a node operator.
  • ether.fi brings a new platform approach to the staking market.
  • Ethereum stakers depositing a minimum of 32 ETH will hold the NFT, which represents the economic interest in the validator.

ether.fi Completes USD 5.3 Million Funding Round Co-led by NIV and Chapter One, Launches Liquid Staking Platform

Retrieved on: 
Wednesday, March 1, 2023
DSRV, Decentralized finance, USS Thomaston (LSD-28), Ecosystem, Chapter One, Maelstrom, ETH, NIV, Risk, Web3, NFT, Capital, DVT, Distribution, LSD, Version One Ventures, Treasury, Virtus Investment Partners, Kiln, Cryptocurrency, Ethereum

LONDON, March 1, 2023 /PRNewswire/ -- ether.fi, a liquid staking protocol designed with decentralization at its core, announced today that it has completed a USD$5.3m funding round co-led by investors North Island Ventures (NIV,) Chapter One, and Node Capital, with participation from Arrington Capital, Maelstrom, Version One Ventures and Purpose Investments.

Key Points: 
  • Node Capital, Arrington Capital, Maelstrom, Version One Ventures, and Purpose Investments also back staking protocol to address issues of centralized staking markets.
  • As a decentralized non-custodial staking solution, ether.fi allows stakers to retain control of their keys while delegating validator operations to a node operator.
  • ether.fi brings a new platform approach to the staking market.
  • Ethereum stakers depositing a minimum of 32 ETH will hold the NFT, which represents the economic interest in the validator.

CEVA Announces its Most Powerful and Efficient DSP Architecture to Date, Addressing the Massive Compute Requirements of 5G-Advanced and Beyond

Retrieved on: 
Thursday, February 23, 2023
Congress, Digital, CEVA, ASIC, Research, Silicon, Architecture, CPU, VLIW, Environment, 5G, RAN, OEM, SOC, DVT, Tier 1, Industrial, DSP, Mobile phone, DSPS

BARCELONA, Spain, Feb. 23, 2023 /PRNewswire/ -- Mobile World Congress CEVA, Inc. (NASDAQ: CEVA), the leading licensor of wireless connectivity and smart sensing technologies and co-creation solutions, today announced its 5th generation CEVA-XC DSP architecture and its most efficient to date, the CEVA-XC20.

Key Points: 
  • base stations, virtualized DU accelerators, and beamforming compute in Massive MIMO radios).
  • Our latest CEVA-XC20 DSP architecture addresses these challenges, leveraging more than 30 years of expertise in cellular DSPs at CEVA to deliver incredible power efficiency for the most intense baseband compute use cases.
  • The first core based on the CEVA-XC20 architecture is the CEVA-XC22 DSP, supporting two execution threads using the groundbreaking DVT scheme.
  • CEVA-XC22 customers can also benefit from ASIC/SoC co-creation services by CEVA's Intrinsix team to help integrate and support system design and modem development.